Journal of clinical medicine
Cure8 research brief
Why This Matters
People with IBD face higher shingles risk, especially when immunosuppressed. This study provides prospective real-world data suggesting the recombinant zoster vaccine is well tolerated in IBD patients, including those on advanced therapies, which is relevant to vaccination decisions.
Who Should Pay Attention
Adult patients with IBD, especially those on advanced biologic or immunosuppressive therapies; gastroenterologists and primary care clinicians involved in vaccination; caregivers advising IBD patients.
Study Snapshot
Story typeClinical Reference
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This prospective single-centre observational study followed 114 adults with inflammatory bowel disease (IBD) who were offered the recombinant zoster vaccine (RZV; Shingrix). Sixty-nine people received at least one dose and 45 declined or postponed vaccination; median follow-up was 17 months.
The authors report no serious vaccine-related adverse events and no meaningful short-term change in IBD activity after vaccination, including among patients on advanced therapies.
Reported herpes zoster (shingles) episodes were self-reported and few (11 total), and the time-dependent analysis did not show a statistically significant association between complete vaccination and subsequent HZ. Prior history of HZ was associated with higher risk of another reported episode.
Because the study was non-randomised with a small number of events, it cannot determine vaccine effectiveness. If you have IBD and are considering RZV, this study adds prospective real-world safety data suggesting short-term safety, including for patients on advanced immunosuppressive therapies. Discuss timing and individual risk with your clinician.
Keep In Mind
This report is a single-centre, non-randomised observational study with a small number of self-reported HZ events and limited follow-up. It assesses short-term safety and cannot establish vaccine effectiveness. The article text is an abstract-level source; findings should be weighed alongside larger studies and clinical guidelines.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationJournal of clinical medicine
AuthorsMorrone GM, Sandri S, Vernero M +3 more
Study typeJournal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedJul 7, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Upadacitinib in Crohn’s Disease Real-World Efficacy and Safety
This study provides real‑world data on upadacitinib’s ability to produce clinical and endoscopic remission in people with Crohn’s disease, information that can help patients and clinicians weigh treatment options.
Upadacitinib Shows Efficacy in Refractory Crohn's Disease - Medscape
This study reports that upadacitinib produced clinical responses and steroid-free remission in a majority of patients with refractory Crohn's disease at 12 weeks, which may be relevant for people who have not responded...
No new safety risks for upadacitinib in IBD at 3 years; uptick in herpes zoster in Crohn’s
This analysis summarizes longer-term safety data for upadacitinib (Rinvoq) in people with moderate to severe ulcerative colitis and Crohn’s disease.